Work

The Role of Uric Acid in Renal and Cardiovascular Function in Patients with Uncomplicated Type 1 Diabetes Mellitus

Year: 2016
Type: dissertation
Abstract: Patients with type 1 diabetes (T1D) have a 30% lifetime risk of developing diabetic nephropathy (DN) despite the use of current available therapies. It is of paramount importance to identify agents that protect patients with T1D from the initiation and progression of DN. Unfortunately, recent renal protection trials in patients with T1D have either failed, demonstrated harm or reported effects that are far below expectations based on data from experimental models. Accumulating evidence suggests that plasma uric acid (PUA) is associated with multiple key pathways involved in the pathogenesis of diabetic complications, including metabolic, cardiovascular and renal abnormalities. Our work is focused on elucidating the pathophysiologic role of PUA in renal and cardiovascular function in patients with T1D. We showed that PUA levels are surprisingly lower in adolescents and young adults with T1D compared to healthy controls (HC) due to glycosuria, which stimulates increased PUA excretion, likely through the GLUT9 isoform 2 transporter. Despite having lower PUA levels, adolescents and young adults with exhibit a negative correlation between PUA and glomerular filtration rate (GFR), possibly due to increased afferent renal arteriolar resistance and reduced renal perfusion. In the context of previous experimental work, our observation suggests that PUA may mediate afferent renal arteriolar disease, causing ischemia to the renal microcirculation, thereby potentiating renal injury. Although not observed in T1D adolescents, the association of higher PUA levels with higher blood pressure emerged in the young adults with T1D. In our final set of experiments, lowering PUA with febuxostat (FBX) for 8 weeks had a modest blood pressure lowering effect in young adults with T1D. FBX enhanced the renal filtration fraction response to clamped hyperglycemia through an increase in efferent renal arteriolar resistance without impacting the RAAS, suggesting that PUA may augment other vasoconstrictor or vasodilatory mechanisms leading to an augmented renal hemodynamic response to hyperglycemia. Longitudinal outcome trials are required to determine whether our physiologic findings impact renal or cardiovascular outcomes in response to PUA lowering therapies in patients with T1D.
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: green
OpenAlex ID: W2729188265
Cites: 129
Cited by:
Related to: 10